Purification of the two components of leucocidin from Staphylococcus aureus

Characterisation of a synergohymenotropic toxin produced by Staphylococcus intermedius

“…The latter toxin (LukS-PV+LukF-PV) was recently cloned and sequenced [20]. It forms, with 7-haemolysin (HlgA, HlgB, HlgC) from S. aureus [7], a family of toxins acting by the synergy [12,33] of two secreted but non-associated proteins of class S (LukS-PV, HlgA, HlgC) and class F (LukF-PV, *Corresponding author. Fax: (33) (88) 25 11 13.…”

“…Since each SHT component of class S and class F components exhibited synergistic activity [12,33], and since class S components bind membranes prior the interaction of the class F components [6], LukS-I and LukF-I were tested in combination (Table 1) also showed a high toxicity (3.8 x 107 U/mg of LukS-I) on canine glass-adherent blood cells, whereas other combinations appeared ineffective on these cells. The haemolytic activity of LukS-I+LukF-I was quite low (5 × 103 U/mg) when tested on rabbit erythrocytes, if compared to the couples HIgA + HlgB and LukS-I + HlgB (5 x 107 U/mg), but the couple HIgA + LukF-I had no more activity.…”

Staphylococcus aureusLukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1

“…The bicomponent leukocidins are a family of secreted staphylococcal toxins that form β-barrel pores through the assembly of two separate polypeptides into heterooligomeric complexes (7,8). A single S. aureus strain can produce up to five different leukotoxins including two versions of γ-hemolysin (HlgAB and HlgCB), leukocidin E/D (LukED), Panton-Valentine leukocidin (PVL), and leukocidin A/B (LukAB, also known as LukGH) (4)(5)(6).…”

Molecular Biology of the Pore-forming Cytolysins fromStaphylococcus aureus,α- andγ-Hemolysins and Leukocidin

“…Woodin first studied the mode of action of leukocidin using purified two components of PVL, S, and F. 26 54) Since the mode of action of ')I·hemolysin was poorly understood, we first studied binding of its components to human erythrocytes. 55) Surprisingly, the precedence of the LukF (or H')II) binding was shown by the following evidence: LukF binding occurred irrespective of whether or not human erythrocytes have been incubated with Hlg2, but no significant binding of Hlg2 took place without the incubation of the erythrocytes with LukF.…”